nucana.com (NCNA) - Gross Profit Margin

Official company branding of NuCana plc (NCNA)

The financial model of NuCana plc (NCNA) is entirely dependent on clinical trial results, although its patent portfolio mitigates these risks. The gross profit margin on this GURU.Markets platform chart confirms this, where the 0.00 level serves as a critical benchmark. The development of nucleoside analogs against resistant lung and ovarian tumors in collaboration with industry behemoths reduces pipeline risks, while treatment programs for liver and colorectal cancer diversify scientific threats.

NCNA (nucana.com) Return on Gross Profit history from 07/04/2022 to 11/20/2026

Financial and market metric breakdowns for nucana.com (NCNA)

- market price and analyst price targets:
Basic company analysis:NuCana plc (NCNA)
Manufactured products of NuCana plc

Gross margin reflects production efficiency by measuring the portion of revenue remaining after covering direct operating costs. By analyzing gross margin growth, an investor can assess a business's ability to generate profit before accounting for administrative expenses. For NuCana plc (NCNA), this metric is supported by a stable British jurisdiction and the humanitarian status of medicine, which minimizes the impact of geopolitical risks on development costs.